All Videos

A panelist discusses how laser treatments demonstrate a strong safety profile and proven efficacy for patients with acne, with clinical studies showing significant reduction in both inflammatory and noninflammatory lesions.

A panelist discusses how laser therapy serves as both a stand-alone alternative and complementary treatment to traditional acne therapies, providing patients with expanded options for managing their skin condition.

A panelist discusses how laser therapy can be customized for different skin types and acne severities through adjustable wavelengths and treatment protocols, offering effective solutions across the spectrum of acne presentations.

One of the Foundation’s top initiatives is its mobile skin cancer screening program, “Destination Healthy Skin.”

A panelist discusses how combining laser therapy with other treatment modalities, such as topical medications, phototherapy, and systemic agents, can produce synergistic effects and better clinical outcomes for resistant skin conditions.

A panelist discusses how laser therapy protocols should be customized based on patients’ financial resources, previous treatment experiences, and commitment level to ensure optimal adherence and therapeutic success.

A panelist discusses how targeted laser therapy offers promising treatment outcomes for chronic skin conditions, such as eczema, psoriasis, and vitiligo, by reducing inflammation, stimulating melanin production, and promoting skin healing through controlled light exposure.

A panelist discusses how the advent of targeted systemic therapies such as dupilumab and nemolizumab has transformed the treatment landscape for prurigo nodularis, offering more effective options for breaking the itch-scratch cycle while maintaining favorable safety profiles compared with traditional systemic treatments.

“As good as we saw results in 1 month, we think we'll see even more remarkable results over the 6 months of treatment,” Edelson said in an interview with Dermatology Times.

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

A panelist discusses how laser treatments have evolved to effectively address diverse skin conditions and aesthetic concerns across different ethnicities, expanding access to personalized care options.

A panelist discusses how the rapid evolution of laser technologies creates challenges for practitioners to stay current with safety protocols, operating procedures, and best practices for different applications.

A panelist discusses how advances in laser technology have improved safety protocols and treatment precision for patients across diverse skin tones, enabling more inclusive and effective cosmetic procedures.

A panelist discusses how combining laser treatments with other modalities, such as radiofrequency or injectables, can enhance clinical outcomes and patient satisfaction when protocols are carefully sequenced and timed.

A panelist discusses how fractional lasers create microscopic treatment zones for controlled healing, whereas nonfractional lasers target broader areas, offering different approaches to skin resurfacing based on patient needs and recovery preferences.

A panelist discusses how recent innovations in topical cream formulations for atopic dermatitis have led to improved efficacy, better tolerability, and enhanced quality of life for patients.

A panelist discusses how combining different therapeutic approaches, such as topical agents with systemic medications, can provide optimal control for patients with severe atopic dermatitis while managing both acute flares and long-term disease maintenance.

A panelist discusses how health care providers can address patients’ concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.

A panelist discusses how the choice between systemic and topical treatments for atopic dermatitis patients should be based on factors like disease severity, affected body surface area, impact on quality of life, and previous treatment response.

A panelist discusses how this patient's history of chronic kidney disease, diabetes, and psychological stress are significant contributing factors to his prurigo nodularis, necessitating a comprehensive treatment approach that addresses both the underlying conditions and the itch-scratch cycle.

TJ Chao, MPAS, PA-C, discusses how systemic treatments for prurigo nodularis are considered for patients with moderate to severe disease, highlighting key patient-specific factors such as comorbidities and disease severity when initiating treatment.

A panelist discusses how diagnostic differentiation of prurigo nodularis requires careful examination of the characteristic firm, hyperkeratotic nodules and consideration of the patient's history of chronic pruritus and scratching behavior, while noting that comorbid atopic dermatitis may influence treatment selection toward dual-targeting therapies.

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.

The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.

A panelist discusses how precision medicine enables targeted atopic dermatitis treatments by matching specific therapies to patients based on their unique disease characteristics and biomarkers

A panelist discusses how initiating topical JAK inhibitors requires thorough patient education about proper application techniques, safety monitoring, and setting realistic expectations for treatment response timelines.

A panelist discusses how supporting patients with atopic dermatitis requires addressing both physical comorbidities and psychological health challenges simultaneously for optimal treatment outcomes.

James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.

A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations.